



PATIENT NAME : ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		

Results

Test	Report	Status	<u>Final</u>

Biological Reference Interval Units

нл	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP AB	OVE 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	11.5 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT	4.10	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT	7.19	4.0 - 10.0	thou/µL
PLATELET COUNT	266	150 - 410	thou/µL
	24.0.1		0/
HEMATOCRIT (PCV)	34.9 Low	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV)	85.2	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.2	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	33.0	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	16.4 High	11.6 - 14.0	%
MENTZER INDEX	20.8		
MEAN PLATELET VOLUME (MPV)	13.2 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	53	40 - 80	%
LYMPHOCYTES	37	20 - 40	%
MONOCYTES	8	2 - 10	%
EOSINOPHILS	2	1 - 6	%
BASOPHILS	0	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT	3.81	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.66	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT	0.58	0.20 - 1.00	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.14	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL

Chandni Garg

Obraraht

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Dr.Pranjali Vasisht LAB HEAD



View Details







PATIENT NAME : ENNA RANI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0080WL007440 PATIENT ID :ENNAF25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 57 Years Female DRAWN : RECEIVED : 23/12/2023 08:37:12 REPORTED : 23/12/2023 19:27:29
Test Report Status Final	Results Biological	Reference Interval Units

NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.4

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020)

106504

This ratio element is a calculated parameter and out of NABL scope.

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Drawht

Dr.Pranjali Vasisht LAB HEAD



Page 2 Of 24

View Details








PATIENT NAME: ENNA RANI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

Biological Reference Interval Units

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECK	JP ABOVE 40FEMALE		
ERYTHROCYTE SEDIMENTATION RATE (E	SR),EDTA		
E.S.R	24 High	0 - 20	mm at 1 hr
METHOD : MODIFIED WESTERGREN			
GLYCOSYLATED HEMOGLOBIN(HBA1C), E BLOOD	DTA WHOLE		
	DTA WHOLE 6.1 High	Non-diabetic Adult < 5.7	%
BLOOD		Pre-diabetes 5.7 - 6.4	
BLOOD		Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or =	
BLOOD		Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = Therapeutic goals: < 7.0	
BLOOD		Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or =	



Diaraht

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD



View Details



Page 3 Of 24







PATIENT NAME: ENNA RANI	REF. DOCTOR :	SELF
	ACCESSION NO : 0080WL007440 PATIENT ID : ENNAF25086680	AGE/SEX : 57 Years Female DRAWN :
DELHI	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29
Test Report Status Final	Results Biological	Reference Interval Units

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Deraraht

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD



Page 4 Of 24

View Report



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





PATIENT NAME: ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		

Test Report Status Final

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE A METHOD : SLIDE AGGLUTINATION POSITIVE

METHOD : SLIDE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Coracalit

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT :

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



etails View Report

Page 5 Of 24








PATIENT NAME : ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080WL007440 PATIENT ID : ENNAF25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Female DRAWN : RECEIVED :23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

	BIOCHEMISTRY	,	
MEDI WHEEL FULL BODY HEALTH CHEC	KUP ABOVE 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	93	74 - 106	mg/dL



mg/dL

METHOD : HEXOKINASE

Diaraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Gneg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Page 6 Of 24

Details







PATIENT NAME : ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0080WL007440 PATIENT ID : ENNAF25086680	AGE/SEX : 57 Years Female DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29
8800465156 Test Report Status <u>Final</u>	Results Biologica	I Reference Interval Units

	GLUCOSE, POST-PRANDIAL, PLASMA		
160			
^ 128_ 96 _	114	103 🖝	
64 - 			
	24-SEP-2022 14:49	23-DEC-2023 13:24	
NormalRange	Date>		
PID PROFILE WITH CALCUL	ATED LDL		
HOLESTEROL, TOTAL	210 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE, ESTER	129	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY DL CHOLESTEROL	46	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG	138 High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL

Coracalit

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Page 7 Of 24



View Details








PATIENT NAME : ENNA RANI		REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 008 PATIENT ID : ENN CLIENT PATIENT ID: ABHA NO :	BOWL007440 AGE/SEX : 57 Years Female NAF25086680 DRAWN : RECEIVED : 23/12/2023 08:37:12 REPORTED : 23/12/2023 19:27:29
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
METHOD : CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE		
NON HDL CHOLESTEROL	46	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
VERY LOW DENSITY LIPOPROTEIN	25.8	Desirable value : mg/dL 10 - 35
METHOD : CALCULATED PARAMETER CHOL/HDL RATIO	4.6 High	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
METHOD : CALCULATED PARAMETER	3.0	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

METHOD : CALCULATED PARAMETER



Drawlit

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD



View Details




Page 8 Of 24








PATIENT NAME: ENNA RANI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		





Diaraht

Chandni Gneg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Page 9 Of 24



View Details







PATIENT NAME : ENNA RANI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0080WL007440 PATIENT ID : ENNAF25086680 CLIENT PATIENT ID:	AGE/SEX :57 Years Female DRAWN : RECEIVED :23/12/2023 08:37:12
DELHI NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :23/12/2023 19:27:29
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C $< $ or =		
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk	1. Three major ASCVD risk factors. 2. Dia	abetes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ictors	
1. Age $>$ or $=$ 45 year	s in males and $>$ or $= 55$ years in females	3. Current Cigarette smoking or tobacco use	
2. Family history of premature ASCVD 4. High blood pressure		4. High blood pressure	
5. Low HDL			
Jower treatment goal	and statin initiation thresholds based on th	no risk catagories proposed by IAL in 2020	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

	0.37	UPTO 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE) BILIRUBIN, DIRECT	0.10	0.00 - 0.30	mg/dL
METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT	0.27	0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	7.2	6.6 - 8.7	g/dL
METHOD : BIURET ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN			

Coracalit

Chandni Gneg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

View Report



Page 10 Of 24







PATIENT NAME: ENNA RANI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		

Test Report Status <u>Final</u>	Results Biological Reference Interval Unit		Interval Units
GLOBULIN	2.7	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
	1 7	10.20	DATIO.
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.7	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	16	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : UV WITHOUT PYRIDOXAL-5 PHOSPHATE	17	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD : PNPP - AMP BUFFER	93	35 - 105	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	26	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD : LACTATE -PYRUVATE	146	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : UREASE - UV	14	6 - 20	mg/dL

Drawht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Gnrg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Details

View Report



Page 11 Of 24


Final





Units

PATIENT NAME: ENNA RANI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007440 AGE/SEX :57 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ENNAF25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:37:12 DELHI ABHA NO REPORTED :23/12/2023 19:27:29 : NEW DELHI 110030 8800465156 Biological Reference Interval **Test Report Status** Results



Deraraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST

mg/dL



Page 12 Of 24

View Report

<u>Final</u>





PATIENT NAME : ENNA RANI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007440 AGE/SEX :57 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ENNAF25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:37:12 DELHÍ REPORTED :23/12/2023 19:27:29 ABHA NO : NEW DELHI 110030 8800465156 Biological Reference Interval **Test Report Status** Results Units

	CREATININE		
1.9			
1.52 -			
1.14 -			
0.76 -	14.0	0.83	
- 	0.69		
0			
Biological Reference Interval: 0.50	24-SEP-2022 11:49 0 - 0.90 mg/dl Date	23-DEC-2023 10:00	
UN/CREAT RATIO			
UN/CREAT RATIO METHOD : CALCULATED PARAMETER	16.87 High	5.00 - 15.00	
RIC ACID, SERUM			
RIC ACID METHOD : URICASE, COLORIMETRIC	7.5 High	2.4 - 5.7	mg
OTAL PROTEIN, SERUM			
DTAL PROTEIN METHOD : BIURET	7.2	6.6 - 8.7	g/c
LBUMIN, SERUM			
LBUMIN METHOD : BROMOCRESOL GREEN	4.5	3.97 - 4.94	g/o

GLOBULIN

Diaraht

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956





Details







mmol/L

mmol/L

mmol/L

PATIENT NAME : ENNA RANI		REF. DOCTOR :	SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080	WL007440	AGE/SEX	:57 Years	Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	PATIENT ID : ENNA CLIENT PATIENT ID : ABHA NO :	F25086680	RECEIVED	: : 23/12/2023 :23/12/2023	
8800465156 Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval	Units
GLOBULIN	2.7	2.0 - 4.0 Neonates Pre Matur		g/	/dL
METHOD : CALCULATED PARAMETER		0.29 - 1.0	4		
ELECTROLYTES (NA/K/CL), SERUM					

ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	144	136 - 145	
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	3.86	3.5 - 5.1	
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	107	98 - 107	

Interpretation(s)

METHOD : ISE INDIRECT

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Drawlit

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Gnrg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





5 D

Page 14 Of 24

View Details







PATIENT NAME: ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ENNAF25086680	DRAWN :
DELHI		RECEIVED : 23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29
8800465156		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Interpretation(s) GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

b>NOTE:
 b>NOTE:
 b>NOTE:
 b>NOTE:
 choose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.
 High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis. Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert

syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease,

Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage,

Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)
 Lower than normal level may be due to:
 Myasthenia Gravis, Muscuophy
 URIC ACID, SERUM-
Couses of Increased levels:</br>
 Joint Intake, OCP, Multiple Sclerosis
 DM, Metabolic syndrome

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Deraraht

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 15 Of 24

View Details







PATIENT NAME: ENNA RANI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		
$\left(\right)$	1	Ι

Т	est	Report	Status	<u>Fina</u>
---	-----	--------	--------	-------------

Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE PHYSICAL EXAMINATION, URINE COLOR PALE YELLOW APPEARANCE SLIGHTLY HAZY CHEMICAL EXAMINATION, URINE 4.7 - 7.5 PH 6.0 METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD SPECIFIC GRAVITY 1.025 1.003 - 1.035 METHOD : REFLECTANCE SPECTROPHOTOMETRY (PKA CHANGE OF PRETREATED POLY ELECTROLYTES) PROTEIN NOT DETECTED NOT DETECTED METHOD : REFLECTANCE SPECTROPHOTOMETRY (PROTEIN-ERROR-OF-INDICATORS PRINCIPLE) NOT DETECTED GLUCOSE NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY(GLUCOSE OXIDAE/	PEROXIDASE METHOD)	
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (SODIUM NITROPRI	JSSIDE REACTION)	
BLOOD	DETECTED (TRACE)	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PEROXIDASE METH	IOD)	
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)		
UROBILINOGEN	NORMAL	NORMAL
METHOD : REFLECTANCE SPECTROPHOTOMETRY - EHRLICH REACTIO	IN	
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF N	ITRATE TO NITRITE	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	2 - 3	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	2-3	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			

Diaraht

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011

Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Page 16 Of 24









PATIENT NAME : ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080WL007440 PATIENT ID : ENNAF25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Female DRAWN : RECEIVED :23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CASTS	NOT DETECTED	
CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION BACTERIA METHOD : MICROSCOPIC EXAMINATION		
YEAST	NOT DETECTED	NOT DETECTED

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis

Coracalit

Dr.Pranjali Vasisht LAB HEAD Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 17 Of 24

View Details







PATIENT NAME : ENNA RANI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007440 AGE/SEX :57 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ENNAF25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:37:12 DELHÍ REPORTED :23/12/2023 19:27:29 ABHA NO : NEW DELHI 110030 8800465156 Biological Reference Interval **Test Report Status** <u>Final</u> Results Units

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Diaraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Details View Report



Page 18 Of 24





PATIENT NAME: ENNA RANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		
	L	

Test Report Status Final

Results

Biological Reference Interval Units

CYTOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE **PAPANICOLAOU SMEAR** TEST METHOD CONVENTIONAL GYNEC CYTOLOGY TWO UNSTAINED CERVICAL SMEARS RECEIVED SPECIMEN TYPE REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY SMEARS ARE SATISFACTORY FOR EVALUATION. SPECIMEN ADEQUACY SMEARS SHOW ADEQUATE CELLULARITY COMPOSED PREDOMINANTLY MICROSCOPY OF INTERMEDIATE SQUAMOUS EPITHELIAL CELLS ALONG WITH FEW SUPERFICIAL SQUAMOUS EPITHELIAL CELLS IN A BACKGROUND OF POLYMORPHS AND BLOOD.ENDOCERVICAL CELLS SEEN.FEW PARABASAL CELLS SEEN.NO EVIDENCE OF MALIGNANCY SEEN. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY **INTERPRETATION / RESULT** REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION.

Chandni Garg

PERFORMED AT :

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Drawht

Dr.Pranjali Vasisht LAB HEAD



View Report

07

Page 19 Of 24





PATIENT NAME: ENNA RANI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0080WL007440 PATIENT ID : ENNAF25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Female DRAWN : RECEIVED :23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29
Test Report Status Final	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE LETTER

REQUEST LETTER

CX/319/23

Chandni Garg

PERFORMED AT :

DR.CHANDNI GARG CONSULTANT PATHOLOGIST

Obraraht

Dr.Pranjali Vasisht LAB HEAD





Page 20 Of 24

346 🗉







PATIENT NAME: ENNA RANI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007440 AGE/SEX :57 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ENNAF25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:37:12 DELHI ABHA NO REPORTED :23/12/2023 19:27:29 : NEW DELHI 110030 8800465156

Test Report Status Final

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR

SAMPLE NOT RECEIVED



PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Page 21 Of 24





View Details







PATIENT NAME : ENNA RANI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007440	AGE/SEX : 57 Years Female
	PATIENT ID : ENNAF25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:37:12
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 19:27:29
8800465156		
(

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE					
MEDI WHEEL FULL BODY HEALTH CH	IECKUP ABOVE 40FEMALE				
THYROID PANEL, SERUM					
T3 METHOD : COMPETITIVE (ECLIA)	116.60	80.00 - 200.00	ng/dL		
T4 METHOD : COMPETITIVE (ECLIA)	7.08	5.10 - 14.10	µg/dL		
TSH (ULTRASENSITIVE)	2.660	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Associa 1st Trimester 0.100 - 2.5 2nd Trimester 0.200 - 3.0 3rd Trimester 0.300 - 3.0	00 000		
METHOD : SANDWICH (ECLIA)					

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions	
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
					Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, Iodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	

Drawht

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Page 22 Of 24

View Details





REF. DOCTOR : SELF



Female

Units

PATIENT NAME: ENNA RANI

Test Report Status

CODE/NAME & ADDRESS : C000138383	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	
F-703, LADO SARAI, MEHRAULISOUTH WEST	
DELHI	
NEW DELHI 110030	
8800465156	

Final

ACCESSION NO : 0080WL007440 AGE/SEX PATIENT ID DRAWN : ENNAF25086680 CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:37:12 ABHA NO REPORTED :23/12/2023 19:27:29 :

Biological Reference Interval

:

:57 Years

4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

Results

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Deraraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT :

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 23 Of 24







PATIENT NAME : ENNA RANI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0080WL007440 PATIENT ID :ENNAF25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Female DRAWN : RECEIVED :23/12/2023 08:37:12 REPORTED :23/12/2023 19:27:29		
Test Report Status Final	Results Biological	Reference Interval Units		

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

i. Specimen received is insufficient or inappropriate

ii. Specimen quality is unsatisfactory

iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Deraraht

Dr.Pranjali Vasisht LAB HEAD Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 24 Of 24

View Details

